An abnormal Ca2+ response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy

Diane Fatkin, Bradley K. McConnell, James O. Mudd, Christopher Semsarian, Ivan G.P. Moskowitz, Frederick J. Schoen, Michael Giewat, Christine E. Seidman, J. G. Seidman

Research output: Contribution to journalArticlepeer-review

180 Scopus citations


Dominant-negative sarcomere protein gene mutations cause familial hypertrophic cardiomyopathy (FHC), a disease characterized by left-ventricular hypertrophy, angina, and dyspnea that can result in sudden death. We report here that a murine model of FHC bearing a cardiac myosin heavy-chain gene missense mutation (αMHC403(/)+), when treated with calcineurin inhibitors or a K+-channel agonist, developed accentuated hypertrophy, worsened histopathology, and was at risk for early death. Despite distinct pharmacologic targets, each agent augmented diastolic Ca2+ concentrations in wild-type cardiac myocytes; αMHC403(/)+ myocytes failed to respond. Pretreatment with a Ca2+-channel antagonist abrogated diastolic Ca2+ changes in wild-type myocytes and prevented the exaggerated hypertrophic response of treated αMHC403(/)+ mice. We conclude that FHC-causing sarcomere protein gene mutations cause abnormal Ca2+ responses that initiate a hypertrophic response. These data define an important Ca2+-dependent step in the pathway by which mutant sarcomere proteins trigger myocyte growth and remodel the heart, provide definitive evidence that environment influences progression of FHC, and suggest a rational therapeutic approach to this prevalent human disease.

Original languageEnglish (US)
Pages (from-to)1351-1359
Number of pages9
JournalJournal of Clinical Investigation
Issue number11
StatePublished - 2000
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'An abnormal Ca2+ response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy'. Together they form a unique fingerprint.

Cite this